GCP
NBRV

GSA Capital Partners’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

GSA Capital Partners’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,299
Closed -$214K – 1990
2021
Q4 		$214K Buy
+14,299
New +$339K 0.03% 1170
2021
Q1 		– Sell
-2,022
Closed -$122K – 1669
2020
Q4 		$122K Buy
+2,022
New +$219K 0.02% 1079

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return
VFA
Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GSA Capital Partners's NBRV Position: Q1 2022 in Review

GSA Capital Partners sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2022, closing a stake of 14,299 shares — an estimated $214K sold.

GSA Capital Partners first reported a position in NBRV in Q4 2020 and held it in 2 quarters. The position peaked at $214K in Q4 2021. 29 funds tracked by Wall St. Rank hold NBRV as of Q1 2022.

  • GSA Capital Partners reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2022 after selling out during the quarter.
  • GSA Capital Partners sold 14,299 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2022, an estimated $214K.
  • GSA Capital Partners first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2020 and held it in 2 quarters.
  • GSA Capital Partners's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $214K in Q4 2021.
  • 29 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2022.

Based on GSA Capital Partners's 13F filing for Q1 2022, filed 11 May 2022.